{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:28Z","timestamp":1740149008699,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173902","81874326","82104274"],"award-info":[{"award-number":["82173902","81874326","82104274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12325-022-02377-x","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T07:03:22Z","timestamp":1670396602000},"page":"658-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pharmacokinetic Drug\u2013Drug Interactions Study between Entecavir and Hydronidone, a Potential Novel Antifibrotic Small Molecule, in Healthy Male Volunteers"],"prefix":"10.1007","volume":"40","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengpeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinping","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"2377_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7629724","author":"R Bansal","year":"2016","unstructured":"Bansal R, Nagorniewicz B, Prakash J. Clinical advancements in the targeted therapies against liver fibrosis. Mediators Inflamm. 2016. https:\/\/doi.org\/10.1155\/2016\/7629724.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2377_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Investig. 2017;127(1):55\u201364. https:\/\/doi.org\/10.1172\/JCI88881.","journal-title":"J Clin Investig"},{"issue":"12","key":"2377_CR3","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","volume":"18","author":"AM Moon","year":"2020","unstructured":"Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18(12):2650\u201366. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.060.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5 Suppl","key":"2377_CR4","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/hep.22881","volume":"49","author":"TJ Liang","year":"2009","unstructured":"Liang TJ. Hepatitis B: the virus and disease. Hepatology (Baltimore, MD). 2009;49(5 Suppl):S13\u201321. https:\/\/doi.org\/10.1002\/hep.22881.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"2377_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","volume":"17","author":"S Cheemerla","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis. 2021;17(5):365\u201370. https:\/\/doi.org\/10.1002\/cld.1061.","journal-title":"Clin Liver Dis"},{"issue":"9963","key":"2377_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s0140-6736(14)61682-2","volume":"385","author":"M Naghavi","year":"2015","unstructured":"Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et\u00a0al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117\u201371. https:\/\/doi.org\/10.1016\/s0140-6736(14)61682-2.","journal-title":"Lancet"},{"key":"2377_CR7","doi-asserted-by":"publisher","DOI":"10.5070\/D32311037239","author":"S Le","year":"2017","unstructured":"Le S, Ansari U, Mumtaz A, Malik K, Patel P, Doyle A, et\u00a0al. Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders. Dermatol Online J. 2017. https:\/\/doi.org\/10.5070\/D32311037239.","journal-title":"Dermatol Online J"},{"issue":"3","key":"2377_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.14218\/jcth.2020.00023","volume":"8","author":"Y-C Guo","year":"2020","unstructured":"Guo Y-C, Lu L-G. Antihepatic fibrosis drugs in clinical trials. J Clin Transl Hepatol. 2020;8(3):304\u201312. https:\/\/doi.org\/10.14218\/jcth.2020.00023.","journal-title":"J Clin Transl Hepatol"},{"key":"2377_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.730176","author":"Z Tan","year":"2021","unstructured":"Tan Z, Sun H, Xue T, Gan C, Liu H, Xie Y, et\u00a0al. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.730176.","journal-title":"Front Cell Dev Biol."},{"issue":"9","key":"2377_CR10","first-page":"657","volume":"27","author":"Chinese Society of Hepatology CMA, Chinese Society of Gastroenterology CMA, Chinese Society of Infectious Diseases CMA","year":"2019","unstructured":"Chinese Society of Hepatology CMA, Chinese Society of Gastroenterology CMA, Chinese Society of Infectious Diseases CMA. Consensus on the diagnosis and therapy of hepatic fibrosis in 2019. Chin J Hepatol. 2019;27(9):657\u201367.","journal-title":"Chin J Hepatol."},{"key":"2377_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cbi.2018.07.008","volume":"292","author":"H-H Hu","year":"2018","unstructured":"Hu H-H, Chen D-Q, Wang Y-N, Feng Y-L, Cao G, Vaziri ND, et\u00a0al. New insights into TGF-beta\/Smad signaling in tissue fibrosis. Chem Biol Interact. 2018;292:76\u201383. https:\/\/doi.org\/10.1016\/j.cbi.2018.07.008.","journal-title":"Chem Biol Interact"},{"issue":"11","key":"2377_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/gut.2006.107136","volume":"55","author":"J Armendariz-Borunda","year":"2006","unstructured":"Armendariz-Borunda J, Islas-Carbajal MC, Meza-Garcia E, Rincon AR, Lucano S, Sandoval AS, et\u00a0al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut. 2006;55(11):1663\u20135. https:\/\/doi.org\/10.1136\/gut.2006.107136.","journal-title":"Gut"},{"key":"2377_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230x-14-131","author":"L Flores-Contreras","year":"2014","unstructured":"Flores-Contreras L, Sandoval-Rodriguez AS, Mena-Enriquez MG, Lucano-Landeros S, Arellano-Olivera I, Alvarez-Alvarez A, et\u00a0al. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C. Bmc Gastroenterol. 2014. https:\/\/doi.org\/10.1186\/1471-230x-14-131.","journal-title":"Bmc Gastroenterol"},{"issue":"10","key":"2377_CR14","first-page":"950","volume":"45","author":"H Liao","year":"2014","unstructured":"Liao H, Li Z, Deng L, Fan H, Luo Y. Hydronidone attenuates renal interstitial fibrosis in rat model of obstructive nephropathy. Chin J Pharm. 2014;45(10):950\u20135.","journal-title":"Chin J Pharm"},{"issue":"22","key":"2377_CR15","first-page":"2409","volume":"35","author":"T Dai","year":"2013","unstructured":"Dai T, Luo T, He Y, Gu X, Tang R, Dong J, et\u00a0al. Effect of atrial fibrosis on atrial structural remodeling and inflammation in atrial fibrillation canines. J Third Military Med Univ. 2013;35(22):2409\u201314.","journal-title":"J Third Military Med Univ"},{"issue":"2","key":"2377_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cgh.2019.07.010","volume":"18","author":"J-L Hou","year":"2020","unstructured":"Hou J-L, Zhao W, Lee C, Hann H-W, Peng C-Y, Tanwandee T, et\u00a0al. Outcomes of long-term treatment of chronic HBV infection with entecavir or other agents from a randomized trial in 24 countries. Clin Gastroenterol Hepatol. 2020;18(2):457. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.010.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"2377_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"T-T Chang","year":"2010","unstructured":"Chang T-T, Liaw Y-F, Wu S-S, Schiff E, Han K-H, Lai C-L, et\u00a0al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886\u201393. https:\/\/doi.org\/10.1002\/hep.23785.","journal-title":"Hepatology"},{"issue":"25","key":"2377_CR18","doi-asserted-by":"publisher","first-page":"7869","DOI":"10.3748\/wjg.v21.i25.7869","volume":"21","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhang Y-G, Wang X, Qi W-Q, Qin S-Y, Liu Z-H, et\u00a0al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol. 2015;21(25):7869\u201376. https:\/\/doi.org\/10.3748\/wjg.v21.i25.7869.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"2377_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/liv.13289","volume":"37","author":"B-Q Wang","year":"2017","unstructured":"Wang B-Q, Wang Y-L, Shi K-Q. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2017;37(2):309\u201310. https:\/\/doi.org\/10.1111\/liv.13289.","journal-title":"Liver Int"},{"key":"2377_CR20","unstructured":"China Food and Drug Administration Good clinical practice guideline. 2010. http:\/\/www.sda.gov.cn\/WS01\/CL0053\/24473.html. Accessed 30 Oct 2010."},{"key":"2377_CR21","unstructured":"ICH Topic E 6 (R1): Guideline for Good Clinical Practice. Note for guidance on good clinical practice. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002874.pdf. Accessed 30 Oct 2010."},{"key":"2377_CR22","unstructured":"World Medical Association Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. 2013. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html. Accessed Oct 2013."},{"issue":"3","key":"2377_CR23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/s2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, et\u00a0al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161\u201376. https:\/\/doi.org\/10.1016\/s2468-1253(16)30181-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"2377_CR24","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1128\/aac.00986-16","volume":"60","author":"X Yang","year":"2016","unstructured":"Yang X, Ma Z, Zhou S, Weng Y, Lei H, Zeng S, et\u00a0al. Multiple drug transporters are involved in renal secretion of entecavir. Antimicrob Agents Chemother. 2016;60(10):6260\u201370. https:\/\/doi.org\/10.1128\/aac.00986-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4\u20135","key":"2377_CR25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ejps.2012.12.024","volume":"48","author":"Q Xu","year":"2013","unstructured":"Xu Q, Wang C, Meng Q, Liu Q, Sun H, Peng J, et\u00a0al. OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. Eur J Pharm Sci. 2013;48(4\u20135):650\u20137. https:\/\/doi.org\/10.1016\/j.ejps.2012.12.024.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2377_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13318-015-0316-z","volume":"42","author":"Y Liu","year":"2017","unstructured":"Liu Y, Wu J, Li Z, Luo Y, Zeng F, Shi S. Tolerability and pharmacokinetics of hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study. Eur J Drug Metab Pharmacokinet. 2017;42(1):37\u201348. https:\/\/doi.org\/10.1007\/s13318-015-0316-z.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"2377_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","volume":"28","author":"SJ Matthews","year":"2006","unstructured":"Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006;28(2):184\u2013203. https:\/\/doi.org\/10.1016\/j.clinthera.2006.02.012.","journal-title":"Clin Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02377-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02377-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02377-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T07:19:44Z","timestamp":1675408784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02377-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2377"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02377-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"23 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}